Brief: Zai Lab Reports Positive Topline Data From Phase 3 Bridging Trial Evaluating Karxt For The Treatment Of Schizophrenia In China
Oct 29 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB REPORTS POSITIVE TOPLINE DATA FROM PHASE 3
BRIDGING
TRIAL EVALUATING KARXT FOR THE TREATMENT OF SCHIZOPHRENIA IN
CHINA
* ZAI LAB LTD - TRIAL MEETS ALL SECONDARY ENDPOINTS WITH
SIGNIFICANT REDUCTIONS IN SCHIZOPHRENIA SYMPTOMS
* ZAI LAB LTD - KARXT SHOWS TOLERABLE SAFETY PROFILE WITH NO
NEW
SAFETY SIGNALS
* ZAI LAB LTD - KARXT SHOWS 9.2-POINT REDUCTION IN PANSS
TOTAL
SCORE AT WEEK 5 VERSUS PLACEBO
* ZAI LAB LTD - TO SUBMIT NDA FOR KARXT TO NMPA IN EARLY
2025
Source text: ID:nBw4H2m5wa
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows